2013-07-15
Abbott agrees to pay $310 million for peripheral stent maker IDEV Technologies and up to $400 million for OptiMedica, which makes laser cataract surgery devices.
Abbott (NYSE:ABT) said it agreed to acquire a pair of companies in the peripheral stent and ophthalmic space for a total of up to $710 million.
The Chicago-ares medical device company said it inked a deal worth $310 million for Webster, Texas-based IDEV Technologies and its Supera Veritas stent for treating peripheral artery disease.
News Well, Mergers & Acquisitions, Optical / Ophthalmic, Peripheral Artery Disease
read more